Takara Bio (4974) · PolicyRestated
Contributing to Human Health through Innovative Biotechnology
First written in FY2021-Q1. 1 of 2 entries say "Restated". Latest entry: FY2021-Q2.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Contributing to Healthcare and Public Health through Innovative Pharmaceuticals and ServicesA theme 13 companies write about · 0 as a headwind · 13 as a tailwind
The whole theme swung hardest in 2025: 1 of 7 companies on the "Worse" side.
9 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2021-Q2RestatedAnnual report
「The Company’s corporate philosophy is to contribute to people’s health through the development of innovative biotechnology, including gene therapy.」
遺伝子治療などの革新的なバイオ技術を通じて健康に貢献する企業理念を再掲している。 - FY2021-Q1First statedAnnual report
「The Company’s corporate philosophy is to contribute to people’s health through the development of innovative biotechnology, including gene therapy.」
Explicitly states contribution to human health through innovative biotechnology, including gene therapy, as the corporate philosophy.